Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025

Core Insights - Bio-Techne Corporation will showcase its latest spatial biology and cell and gene therapy workflow solutions at the ASGCT 2025 meeting in New Orleans from May 13th to 17th [1] - The company will highlight advancements in cell and gene therapy development, including the RNAscope™ protease-free workflow and ProPak™ GMP cytokines [2][4] - Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people globally [5] Product Highlights - The RNAscope™ protease-free workflow allows visualization of biodistribution of AAV vectors, transgene mRNA, and small RNAs [2] - ProPak™ GMP cytokines are designed for closed-system cell therapy manufacturing, featuring dose-optimized, single-use bags [2] - The Simple Western Leo™ System enables simultaneous processing of up to 100 samples in a single 3-hour run [2] Symposium and Presentations - ACD's symposium will feature innovations with RNAscope technology, including NextGen RNAscope™ Multiomics Solutions [3] - A talk on protein quantitation applications to advance gene therapy development will be presented by guest speakers from Sangamo Therapeutics and Nervosave Therapeutics [3][6] - Additional presentations will cover AI-designed AAV capsids and RNA gene writer activity in therapeutic contexts [6]